Comparative Efficacy (DAS28 remission) of Targeted Immune Modulators for Rheumatoid Arthritis: A Network Meta-Analysis
Abstract Background The objective of the study was to evaluate the relative efficacy of targeted immune modulators (TIMs) in TIM-naïve/mixed (≤ 20% TIM-experienced) and TIM-experienced (> 20% TIM-experienced) adults with moderately-to-severe rheumatoid arthritis with an inadequate response or intolerance to conventional disease-modifying antirheumatic drugs (cDMARDs). Methods A fixed effects Bayesian network meta-analysis (NMA) was performed using published study-level data form 41 randomized controlled trials (RCTs), identified from 2 recent systematic literature reviews conducted by the Institute for Clinical and Economic Review, and 2 additional phase III trials for filgotinib (FINCH-1, FINCH-2). RCTs that compared TIMs to each other, cDMARD or placebo were included. Treatments included Janus kinase (JAK) inhibitors, tumor necrosis factor alpha inhibitors (TNFi), and other non-TNFis. Efficacy was defined as achieving remission with a DAS28 score < 2.6 at 12 and 24 weeks. Results In the 12-week analysis for the TIM-naïve/mixed population, all TIMs combined with cDMARD were more likely to achieve remission compared to cDMARD alone (statistically significant), with intravenous tocilizumab showing a substantially greater magnitude of effect (odds ratio = 19.36, 95% credible interval: 11.01, 38.16). Similarly, in the 24-week analysis, intravenous and subcutaneous tocilizumab showed the highest odds ratio of achieving DAS28 remission compared to cDMARD. Similar trends were observed for the analyses on monotherapy or TIM-experienced population. Conclusion This NMA demonstrated that tocilizumab is associated with a greater likelihood of remission (DAS28 < 2.6) at 12 and 24 weeks compared to most other TIMs including new JAK inhibitors, when used in combination with a cDMARD or as monotherapy, among TIM-naïve/mixed or TIM-experienced populations..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ResearchSquare.com - (2021) vom: 17. März Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Best, Jennie H. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-127939/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA033962065 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA033962065 | ||
| 003 | DE-627 | ||
| 005 | 20230429173734.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-127939/v1 |2 doi | |
| 035 | |a (DE-627)XRA033962065 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-127939/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Best, Jennie H. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative Efficacy (DAS28 remission) of Targeted Immune Modulators for Rheumatoid Arthritis: A Network Meta-Analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background The objective of the study was to evaluate the relative efficacy of targeted immune modulators (TIMs) in TIM-naïve/mixed (≤ 20% TIM-experienced) and TIM-experienced (> 20% TIM-experienced) adults with moderately-to-severe rheumatoid arthritis with an inadequate response or intolerance to conventional disease-modifying antirheumatic drugs (cDMARDs). Methods A fixed effects Bayesian network meta-analysis (NMA) was performed using published study-level data form 41 randomized controlled trials (RCTs), identified from 2 recent systematic literature reviews conducted by the Institute for Clinical and Economic Review, and 2 additional phase III trials for filgotinib (FINCH-1, FINCH-2). RCTs that compared TIMs to each other, cDMARD or placebo were included. Treatments included Janus kinase (JAK) inhibitors, tumor necrosis factor alpha inhibitors (TNFi), and other non-TNFis. Efficacy was defined as achieving remission with a DAS28 score < 2.6 at 12 and 24 weeks. Results In the 12-week analysis for the TIM-naïve/mixed population, all TIMs combined with cDMARD were more likely to achieve remission compared to cDMARD alone (statistically significant), with intravenous tocilizumab showing a substantially greater magnitude of effect (odds ratio = 19.36, 95% credible interval: 11.01, 38.16). Similarly, in the 24-week analysis, intravenous and subcutaneous tocilizumab showed the highest odds ratio of achieving DAS28 remission compared to cDMARD. Similar trends were observed for the analyses on monotherapy or TIM-experienced population. Conclusion This NMA demonstrated that tocilizumab is associated with a greater likelihood of remission (DAS28 < 2.6) at 12 and 24 weeks compared to most other TIMs including new JAK inhibitors, when used in combination with a cDMARD or as monotherapy, among TIM-naïve/mixed or TIM-experienced populations. | ||
| 700 | 1 | |a Kuang, Yuting |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yilin |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Rajpal |e verfasserin |4 aut | |
| 700 | 1 | |a Karabis, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Uyei, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Reiss, William |e verfasserin |4 aut | |
| 700 | 1 | |a Dang, Joseph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2021) vom: 17. März |
| 773 | 1 | 8 | |g year:2021 |g day:17 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-127939/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 17 |c 03 | ||
| 953 | |2 045F |a 570 | ||